Recent studies have suggested that obesity is associated with lower serum prostate-specific
antigen levels, perhaps influencing the recommendation for prostate biopsy and potentially
explaining part of the observed poorer prognosis among obese men. African-American
men have the greatest rates of prostate cancer and are more likely to die of the disease,
making early detection a priority in this group. We present findings from the Flint
Men’s Health Study, a study of African-American men, that are consistent with most
studies suggesting that overweight men have prostate-specific antigen levels that
are 0.15 to 0.30 ng/mL lower than those who are not overweight. We have coupled our
results with a systematic review of publications in this area.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to UrologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.N Engl J Med. 1987; 317: 909-916
- Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker.Cancer. 2004; 101: 894-904
- Prostate cancer and prostate-specific antigen: the more we know, the less we understand.J Natl Cancer Inst. 2003; 95: 1027-1028
- Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter.N Engl J Med. 2004; 350: 2239-2246
- Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification.Arch Ital Urol Androl. 2006; 78: 125-129
- The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?.J Urol. 2004; 172: 1297-1301
- Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins.J Urol. 2004; 172: 520-524
- Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy.J Clin Oncol. 2004; 22: 439-445
- Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy.Urology. 2001; 58: 723-728
- Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial.Cancer Epidemiol Biomarkers Prev. 2006; 15: 1977-1983
- Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort.Cancer Epidemiol Biomarkers Prev. 2007; 16: 63-69
- Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy.Clin Cancer Res. 2005; 11: 6889-6894
- Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality.Cancer. 2007; 109: 675-684
- Obesity and prostate cancer: making sense out of apparently conflicting data.Epidemiol Rev. 2007; 29: 88-97
- The association of body mass index and prostate-specific antigen in a population-based study.Cancer. 2005; 103: 1092-1095
- Age-specific distribution of serum prostate-specific antigen in a community-based study of African-American men.Urology. 2001; 57: 91-96
- Potential selection bias in a community-based study of PSA levels in African-American men.J Clin Epidemiol. 2001; 54: 142-148
- Waist circumference as a measure for indicating need for weight management.BMJ. 1995; 311: 158-161
- Prevalence of overweight and obesity in theUnited States, 1999–2004.JAMA. 2006; 295: 1549-1555
- (Accessed June 20, 2007)
- Economic costs of obesity and inactivity.Med Sci Sports Exerc. 1999; 31: S663-S667
- The escalating pandemics of obesity and sedentary lifestyle: a call to action for clinicians.Arch Intern Med. 2004; 164: 249-258
- Platelet activation in obese women: role of inflammation and oxidant stress.JAMA. 2002; 288: 2008-2014
- Central obesity and breast cancer risk: a systematic review.Obes Rev. 2003; 4: 157-173
- Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review.Cancer Epidemiol Biomarkers Prev. 2002; 11: 1531-1543
- Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women.Eur J Endocrinol. 2004; 150: 161-171
- Association between insulin-like growth factor-I: insulin-like growth factor-binding protein-1 ratio and metabolic and anthropometric factors in men and women.Cancer Epidemiol Biomarkers Prev. 2004; 13: 166-170
- Advances in cancer epidemiology: understanding causal mechanisms and the evidence for implementing interventions.Ann Rev Pub Health. 2005; 26: 37-60
- Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy.J Clin Oncol. 2004; 22: 439-445
- Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group.J Clin Oncol. 2004; 22: 446-453
- Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States.Cancer Epidemiol Biomarkers Prev. 2001; 10: 345-353
- Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.N Engl J Med. 2003; 348: 1625-1638
- Obesity and prostate cancer: epidemiology and clinical implications.Eur Urol. 2007; 52: 331-343
- Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.J Natl Cancer Inst. 2006; 98: 529-534
- Prostate cancer screening practices and cancer control research (United States).Cancer Causes Control. 2002; 13: 1-5
- Prostate specific antigen in a community-based sample of men without prostate cancer: correlations with prostate volume, age, body mass index, and symptoms of prostatism.Prostate. 1995; 27: 241-249
- Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men.J Urol. 1998; 160: 1734-1738
- Relationship of body mass index and prostate specific antigen in a population-based study.Urol Oncol. 2004; 22: 127-131
- Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase.Cancer. 2006; 106: 320-328
- Effects of obesity and height on prostate specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men.Cancer. 2006; 107: 2361-2367
- Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program.Urology. 2005; 65: 708-712
- Obesity is negatively associated with prostate-specific antigen in U.S. men, 2001–2004.Cancer Epidemiol Biomarkers Prev. 2007; 16: 70-76
- Influence of age, anthropometry, and hepatic and renal function on serum prostate-specific antigen levels in healthy middle-age men.Urology. 2003; 61: 132-136
- Influence of anthropometric measurements, age, and prostate volume on prostate-specific antigen levels in men with a low risk of prostate cancer.Urology. 2005; 66: 819-823
- The association between body size, prostate volume and prostate-specific antigen.Prostate Cancer Prostatic Dis. 2007; 10: 137-142
Article info
Publication history
Published online: February 27, 2008
Accepted:
November 12,
2007
Received:
August 28,
2007
Footnotes
This work was supported by the National Institutes of Health Specialized Program of Research Excellence (SPORE) grant P50CA89568.
Identification
Copyright
© 2008 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
